Caladrix is a CNS-focused biotechnology company pioneering disease-modifying therapeutics for Alzheimer’s and related tauopathies. Founded in 2025, our mission is to harness the brain’s intrinsic clearance pathways—starting with ABCC1, a genetically validated efflux transporter that exports neurotoxic substrates such as amyloid-beta and inflammatory mediators.

Our lead candidate, C-001, is an orally available small molecule designed to activate ABCC1. Unlike monoclonal antibody therapies, C-001 avoids ARIA risk, eliminates the need for infusion clinics, and directly restores the brain’s natural protein homeostasis. Preclinical efficacy, translational biomarker validation, and a successful human PoC study underpin our clinical development strategy.

Caladrix’s Phase 1 trial begins in H1 2026. A 300-patient Phase 2 is slated for 2028. Our pipeline includes candidates for frontotemporal dementia and other tauopathies, as well as modified-release formulations to ensure scalability and adherence.

With a strong IP estate, world-class collaborators, and a scientific team comprising Clarivate’s Highly Cited researchers, Caladrix is positioned to lead the next generation of non-immunologic neurodegenerative therapies.

Melbourne (HQ / Clinical Trials) | Hamburg (R&D) | Palo Alto 

Partner with us: bd@caladrix.bio | General: info@caladrix.bio

Caladrix

Org chart

Teams

Offices